89459-25-6
89459-25-6
Chemical Structure
DACA
- CAS No.: 89459-25-6
- Formula:C18H19N3O
- Molecular Weight:293.36
IUPAC Name: N-(2-(dimethylamino)ethyl)acridine-4-carboxamide
InChIKey: XBGNERSKEKDZDS-UHFFFAOYSA-N
SMILES: O=C(C1=CC=CC2=CC3=CC=CC=C3N=C12)NCCN(C)C
Biological Activity: DACA (XR 5000) is a potential and blood-brain barrier-penetrating topoisomerase I and II inhibitor. DACA can be used in the research of colorectal cancer, leukemia and lung cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DACA | 98.89% | DACA (XR 5000) is a potential and blood-brain barrier-penetrating topoisomerase I and II inhibitor. DACA can be used in the research of colorectal cancer, leukemia and lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DACA (Standard) | ≥98% | DACA (Standard) is the analytical standard of DACA (HY-100777). This product is intended for research and analytical applications. DACA (XR 5000) is a blood-brain barrier-penetrating topoisomerase I and II inhibitor. DACA can be used in the research of colorectal cancer, leukemia and lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Padget K, et al. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells. Biochem Pharmacol. 2000;60(6):817-821. [Content Brief]
- [2]. Dittrich C, et al. Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. Eur J Cancer. 2003 Feb;39(3):330-4. [Content Brief]
- [3]. Caponigro F, et al. Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. Eur J Cancer. 2002 Jan;38(1):70-4. [Content Brief]
- [4]. Twelves CJ, et al. Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee. Br J Cancer. 1999 Aug;80(11):1786-91. [Content Brief]
